| UHC Surest Medical and Drug | Qalsody® (Tofersen) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Surest Medical and Drug | RNA-Targeted Therapies (Amvuttra® and Onpattro®) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Surest Medical and Drug | Trogarzo® (Ibalizumab-Uiyk) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Surest Medical and Drug | Veopoz® (Pozelimab-Bbfg) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| BCBS North Carolina | Adaptive Behavioral Treatment for Autism Spectrum Disorders | Providers | 2025-06-01 |
| BCBS North Carolina | Ambulatory Event Monitors and Outpatient Cardiac Telemetry | Providers | 2025-06-01 |
| BCBS North Carolina | Amniotic Membrane and Amniotic Fluid Injections for Ophthalmic Indications | Providers | 2025-06-01 |
| BCBS North Carolina | Aqueous Shunts and Devices for Glaucoma | Providers | 2025-06-01 |
| BCBS North Carolina | Artificial Pancreas Device Systems | Providers | 2025-06-01 |
| BCBS North Carolina | Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions | Providers | 2025-06-01 |